Chiesi Group expands global manufacturing with US$464M investment in Italy

ITALY—The Italian pharmaceutical company Chiesi Group has announced a major investment of €430 million (US$464 million) to rejuvenate a historic manufacturing site in Nerviano, Milan, as part of its global expansion strategy.

This investment, spread over the period from 2025 to 2030, aims to transform the 124,000-square-meter (1.33 million-square-foot) industrial area into an international center of excellence for healthcare product manufacturing.

The redevelopment includes the construction of a state-of-the-art facility to produce sustainable, carbon-minimal inhalers, dry powder inhalers, and sterile biological products.

Once operational, the site is expected to generate around 300 new jobs by 2029.

Additionally, the facility will feature over 3,000 square meters (32,292 square feet) of laboratory space and a photovoltaic park to ensure energy self-sufficiency.

Chiesi also plans to regenerate the adjacent 20,000-square-meter (215,278 square feet) wooded area to enhance sustainability efforts.

This location holds historical significance as it was originally established in 1965 as an oncology research center by Farmitalia Carlo Erba.

Over the years, it changed ownership multiple times before its closure in 2024.

Speaking about the project, Chiesi CEO Giuseppe Accogli emphasized Nerviano’s strategic location and its potential to serve as a hub to produce next-generation inhalers.

He stated that this initiative would strengthen Chiesi’s presence in Italy and Europe while fostering growth opportunities for the local community.

The Nerviano investment forms part of Chiesi’s broader global industrial strategy, which includes significant developments in other regions.

In 2024 Chiesi committed €10 million (US$10.8 million) to expand its manufacturing facility in France and create 100 jobs.

Furthermore, the company has recently inaugurated its Biotech Center of Excellence in Parma, investing €400 million (USS$432 million).

This center focuses on developing monoclonal antibodies and other proteins while integrating research and production under one roof for improved efficiency.

Overall, these initiatives underscore Chiesi’s commitment to innovation and sustainability in healthcare manufacturing while supporting local economies and advancing global health solutions.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.